| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human QTRT2 recombinant protein (Position: Q142-H386) was used as the immunogen for the QTRT2 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
QTRT2 Antibody / Queuine tRNA-ribosyltransferase subunit 2 is a anti-QTRT2 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), ELISA with listed reactivity in Human, Mouse, Rat.
Key elements and design rationale
- Target: QTRT2
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, ELISA
Biological background
Structurally, QTRT2 is a ~47 kDa protein that shares homology with QTRT1 but lacks catalytic residues. Instead, QTRT2 functions as a structural subunit that stabilizes the heterodimer and facilitates substrate recognition. QTRT2 localizes to the cytoplasm where tRNA modification occurs. It is conserved across eukaryotes, reflecting its fundamental role in translation regulation.
Functionally, QTRT2 supports tRNA modification that improves translational fidelity and codon-anticodon interactions. Queuine modification affects protein synthesis rates, cellular stress responses, and adaptation to nutrient availability. Researchers use QTRT2 antibody to investigate RNA modifications, translation quality control, and metabolic regulation.
Clinically, defects in queuine modification have been associated with cancer, neurodevelopmental disorders, and infection. Altered expression of QTRT2 has been reported in some tumors, suggesting a role in metabolic reprogramming and growth. Because RNA modifications are emerging therapeutic targets, QTRT2 is under active investigation.
Experimentally, QTRT2 antibody is applied in western blotting to detect the ~47 kDa protein, in immunofluorescence microscopy to study cytoplasmic localization, and in immunoprecipitation to analyze QTRT1-QTRT2 complexes. Functional assays combining QTRT2 antibody with RNA analysis confirm its role in tRNA modification.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
